

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-17. (Canceled)

18. (Previously presented) A polynucleotide encoding a fusion protein, the fusion protein comprising
at least one pan DR binding peptide comprising AKFVAAWTLKAAA (SEQ ID NO:22) and at least one CTL-inducing peptide.

19. (Previously presented) An expression vector comprising the polynucleotide of claim 18.

20. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises multiple pan DR peptides.

21. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises a homopolymer of pan DR peptides.

22. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises a heteropolymer of pan DR peptides.

23. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises a heteropolymer with repeating units.

24. (Canceled)

25. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises an antibody-inducing peptide.

26-65. (Canceled)

66. (Previously presented) A polynucleotide encoding a fusion protein, the fusion protein comprising at least one pan DR binding peptide comprising AKFVAAWTLKAAA (SEQ ID NO:22) and at least one T helper peptide.

67. (Previously presented) An expression vector comprising the polynucleotide of claim 66.

68. (Previously presented) The polynucleotide of claim 66, wherein the fusion protein comprises multiple pan DR peptides.

69. (Previously presented) The polynucleotide of claim 66, wherein the fusion protein comprises a homopolymer of pan DR peptides.

70. (Previously presented) The polynucleotide of claim 66, wherein the fusion protein comprises a heteropolymer of pan DR peptides.

71. (Previously presented) The polynucleotide of claim 66, wherein the fusion protein further comprises a heteropolymer with repeating units.

72. (Previously presented) The polynucleotide of claim 66, wherein the fusion protein further comprises an antibody-inducing peptide.